Latest research on FTY720

Fingolimod is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis.

FTY720 dosage

From the day of the 3rd vaccination through SFI, mice were treated intraperitoneally every other day, with doses of 20 μg FTY720 (Cayman Chemical, Cat# 10006292) per mouse (1 mg/kg) in a final volume of 0.2 ml. [source, 2015]
FTY720 (fingolimod/Gilenya™) was administered p.o. at a single dosage of 0.5 mg/kg in 200 μl of 2% 2-hydroxypropyl-β-cyclodextran (HβC; Sigma-Aldrich). [source, 2015]
FTY720 was given by IP injection at an initial dose of 50 μg/mouse followed by daily maintenance injection at a dose of 5 μg/mouse. [source, 2015]
A double-blind, placebo-controlled study evaluating fingolimod dosages of 0.5 or 1.25 mg/day, termed FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis), revealed a 54% relative reduction in ARR (0.18, 0.16, and 0.40 for 0.5 mg of fingolimod, 1.25 mg of fingolimod, and placebo, respectively). [source, 2015]
A 12-month, double-dummy phase III study involving patients with RRMS (TRANSFORMS: TRial Assessing INjectable INterferon vs. FTY720 Oral in RRMS) compared oral fingolimod at daily doses of either 0.5 or 1.25 mg with intramuscular IFNβ-1a at a weekly dose of 30 µg. [source, 2015]
Depending on the experiment, cells were treated at the following doses/times: 50 ng/ml PDGF-AA for 10 min (R&D Systems, Minneapolis, MN: 221-AA); 50 μM LY294002 for 1 h (Cell Signaling, Danvers, MA: 9901); 10 nM Rapamycin for 24 h (MP Biomedicals, Santa Ana, California: 159346); 200 nM OA for 3 h (Cell Signaling: 5934); and FTY720 for 5 h (Sigma-Aldrich, St. Louis, MO: SML0700-5MG). [source, 2015]
Subsequently the cells were treated for 24, 48 and 72 h with different doses of sorafenib alone or in combination with FTY720 or vehicle (0.04% DMSO). [source, 2015]
Dose–response curves were constructed for treatment with FTY720. [source, 2015]
Thereafter, the cells were treated for 6, 12, or 24 h with different doses of sorafenib/sorafenib and FTY720 or DMSO as indicated in the Results section. [source, 2015]
Subsequently the cells were treated for 24 and 48 h with different doses of sorafenib alone or in combination with FTY720 or vehicle (0.04% DMSO). [source, 2015]